Change in cardiac function (change in fractional shortening) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Any AIS irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN2+ associated with HPV16/18. · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18. (high certainty).
1 finding from 1 review
Intervention not reported
Adeno carcinoma in situ (AIS) associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower adeno carcinoma in situ (AIS) associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention showed no clear difference in serious adverse events (high certainty).
1 finding from 1 review
Intervention not reported
Deaths · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention showed no clear difference in deaths (low certainty).
1 finding from 1 review
Intervention not reported
Elective termination/induced abortion · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in elective termination/induced abortion (high certainty).
1 finding from 1 review
Intervention not reported
Stillbirth · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in stillbirth (moderate certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
Babies born with congenital malformations · adolescent girls and women aged 15 to 45 years who became pregnant during the study
The intervention showed no clear difference in babies born with congenital malformations (moderate certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine (high certainty).
1 finding from 1 review